The success of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in the treatment of obesity and T2DM, including a direct impact on cardiovascular and renal outcomes in T2DM, led to an increase in potential drugs with higher efficacy, including pure GLP-1RAs or dual or triple agonists combined with other gastrointestinal peptides [79]. Here, GLP1R is linked to type 2 diabetes mellitus.